Canadian drug firms have stopped distributing ranitidine antacid products due to contamination with a probable carcinogen while the author of a citizen petition to the the US Food and Drug Administration argues to withdraw the ingredient globally.
In a 17 September statement, Health Canada said it took the “interim, precautionary measure” of asking companies not to distribute...